Android
Zerodha Broker (Free Delivery)

India's No. 1 Broker with Best Software Trade @ Flat Rs 20

Open Instant Account
Price table
Date Open High Low Close Volume Delivery % 20-Day SMA 50-Day SMA 200-Day SMA
24-Jun-2021 641.00 642.75 626.00 631.25 1106106 29.90 627.75 601.75 517.35
23-Jun-2021 645.00 646.95 636.00 638.95 852001 30.39 626.50 599.10 516.60
22-Jun-2021 646.00 649.85 638.60 640.30 1417530 42.84 625.00 596.90 515.85
21-Jun-2021 638.00 647.45 632.75 641.15 1227966 36.81 623.05 594.20 515.00
18-Jun-2021 643.00 647.15 626.00 640.40 1921799 38.47 621.25 591.45 514.25
17-Jun-2021 639.90 653.50 630.00 639.50 2709838 37.46 619.60 588.80 513.55
16-Jun-2021 641.20 653.90 636.55 642.70 3338407 33.26 617.95 585.55 512.80
Key Data
  • Market cap 16088.00 CR.
  • Book value 230.00
  • Stock P/E 20
  • Dividend Yield 0.44%
  • ROCE 13.70%
  • ROE 13.00%
  • Sales Growth (3Y) 0.00%
  • Face Value (3Y) 1.00
GLENMARK Share Price:

GLENMARK share is currently trading at 631.25 at the PE of 20.

The 52-week range of GLENMARK share price is 405.00 ~ 658.20

GLENMARK share has a current face value of ₹1.00/-

GLENMARK Share Price History:

GLENMARK IPO was launched on Jun-24-02021 at the issue price of 100.00.

The Face Value of GLENMARK share was 10.00. With the IPO, GLENMARK had raised 250.00.

Profile

GLENMARK

Glenmark Pharmaceuticals Limited or GLENMARK

Glenmark Pharmaceuticals was being incorporated in 1977, and then it entered into the dermatology market by 1979 via the launch of its Candid Cream. Soon it became a leading player in the discovery of new molecules both NCEs (new chemical entity) and NBEs (new biological entity) with the help of eight molecules in various stages of the clinical development. It also operates in the formulation business in over 95 countries, w ... hich also includes India. It has a significant presence in branded generics markets across emerging economies, including India. And its subsidiary, named Glenmark Generics Limited has a fast growing and robust US generics business. It also markets APIs to regulated & semi-regulated countries and employs nearly 6000 people in over 80 countries worldwide. It has approximately twelve manufacturing facilities in over four countries and also has five R&D centers. The Glenmark was also chosen as one of the "Best Pharma Company in the World – SME" and "Best Company across emerging markets" for 2008 by SCRIP, it is also the most significant selling as well as the most respected pharmaceutical magazine in the world. And then Forbes, which is another leading international publication, recognized Glenmark as the "Best under a Billion Dollar companies in Asia" for 2008. The vision of this company is to emerge as a leading integrated research-based, global pharmaceutical company and over the decades, it has established itself as a leading player in the discovery of new molecules both NCEs (New Chemical Entity) as well as NBEs (New Biological Entity). Now, they have several molecules in various stages of the preclinical and clinical development, and it is also primarily focused in the areas of Oncology, Respiratory & Dermatology. The generics business services the requirements of the developed markets like US & Western Europe and API business sells its products in approximately 80 countries worldwide which includes the US, and various other countries in the EU, and South America and India. And with the 17 manufacturing facilities and 5 R&D centers which are dedicated to the goal of enriching lives across the world and they believe that the real force behind their continued successes is the dedicated employees from across 50 nationalities, committed to creating 'A new way for a new world.'

Here are some of the Business area of the company

  1. Specialty Business: Drug Discovery:
The breaking drug discovery effort is the prime focus in the areas of inflammation [asthma/COPD, rheumatoid arthritis, etc.], metabolic disorders [diabetes, obesity, and much more.] And pain [neuropathic pain and inflammatory pain]. It also has a robust pipeline which includes 13 molecules in various stages of preclinical & clinical development. And out of these, eight molecules are in clinical trials. Such types of molecules in clinical development are mainly used to focus on advanced treatments for chronic/debilitating diseases, and they are potential blockbusters with potential peak sales opportunity for each molecule being within the range of $1 billion to $3 billion.
  1. Specialty Business: Formulations Business:
This business is currently organized around four major regions, which are India, Latin America, and Central Eastern Europe and Semi Regulated Markets of Africa/Asia/CIS. This business focuses on therapeutic areas such as dermatology, anti-infective, respiratory, cardiac, diabetes, gynecology, CNS, and lastly oncology. Also, India has become one of the largest markets in terms of revenue source for the organization. It has five manufacturing facilities; in which three in India and the other two are overseas. Several regulatory bodies are approving all such facilities.

The Milestones:

  1. 2010:
The Glenmark Pharmaceuticals Ltd has entered into a settlement and the license agreement with Sepracor Incorporation to market generic Eszopiclone tablets.
  1. 2011:
  • Glenmark wins Two Prestigious Global Recognitions at SCRIP Awards 2011.
  • Glenmark forays into Cosmeceutical Segment.
  1. 2012:
Forest Laboratories and Glenmark Sign Development Agreement for Worldwide Collaboration on Novel Agents to treat Chronic Inflammatory Conditions."

Read More
Trend Analysis
  • Short Term Trend :
    Up
  • Medium Term Trend :
    Up
  • Long Term Trend :
    Up

Are you friends with trend?

There is a saying in stock market, "Trend is your best friend"

It means, a good trader doesn't place his money against the trend. Many new traders lose money because they are trying to catch trend reversals but seasoned traders wait for a clear trend to emerge before taking the trade in the direction of trend.

Day Technicals

What is Opening Range Breakout?

An opening range breakout is breaking out of the day's range after a stock has moved for some time in a sideways trend. In technical terms, its a breakout from the support and resistance level in an upward or downward trend.

NR7

What is NR7 trading strategy?

Narrow Range trading strategy or NR7 Trading strategy is a breakout based method which assumes that the price of security trends up or down after a brief consolidation in a narrow range.

Opening Price clues

How to use Opening Price Clues in your trades?

If the stock has same open and high after it has traded for some time, it implies there was a consistent selling pressure that didn't allow the stock to move higher from the opening price. Similarly, if the stock has same open and low price, it implies there was a consistent buying intent that kept the stock price above the opening price.

Day High Low Range
TIME LOWEST HIGHEST
10 AM - -
11 AM - -
12 PM - -
1 PM - -
2 PM - -
Japanese Candlestick Patterns
Candle Pattern 1 :None
Candle Pattern 2 : None
Candle Pattern 3 :None
Candlestick Price Action
Lower High Lower Low
Pivot Points
Name S4 S3 S2 S1 Pivot Points R1 R2 R3 R4
classic 607.78 618.73 629.68 634.32 640.63 645.27 651.58 662.53 673.48
woodie's 617.63 628.58 632.29 639.52 643.24 650.48 654.19 661.42 672.38
fibonacci - 629.68 633.86 636.45 640.63 644.82 647.40 651.58 -
camarilla 632.93 635.94 636.94 637.95 -- 639.95 640.96 641.96 644.97
Past Performance & Moving Averages
Day’s LOW HIGH RANGE SMA Stock PERFORMANCE Nifty PERFORMANCE
10 DAY
626.00
658.20
641.19 0.62 % 0.52 %
20 DAY
578.25
658.20
627.74 4.36 % 0.41 %
50 DAY
484.85
658.20
601.75 14.90 % 8.14 %
100 DAY
442.05
658.20
541.67 36.18 % 5.35 %
200 DAY
441.70
658.20
517.37 27.28 % 18.46 %
YTD
442.05
658.20
536.62 29.42 % 12.12 %
52 Week
405.00
658.20
504.04 34.80 % 32.71 %

Why are moving Averages important in technical Analysis?

An opening range breakout is breaking out of the day's range after a stock has moved for some time in a sideways trend. In technical terms, its a breakout from the support and resistance level in an upward or downward trend.

Gaps On Day Chart
Unfilled Gap Up On 2020-04-13
253.00 ~ 250.75 SUPPORT
Unfilled Gap Down On 2017-05-12
839.00 ~ 888.05 RESISTANCE
Industry Growth Rate

In Last 1 Year the industry has grown by 9.72 %

In Last 5 Year the industry has grown by 6.14 %

Peer comparison

Sales

COMPANY NAME 2015 2016 2017 2018 2019 2020
GLENMARK 6563.00 7562.00 9079.00 9074.00 9865.00 10641.00
SUNPHARMA 27392.00 28487.00 31578.00 26489.00 29066.00 32838.00
LUPIN 12770.00 14256.00 17367.00 15797.00 16718.00 15375.00
DRREDDY 15023.00 15568.00 14196.00 14281.00 15448.00 17517.00
AUROPHARMA 12103.00 13772.00 14910.00 16463.00 19564.00 23099.00
Total 73851.00 79645.00 87130.00 82104.00 90661.00 99470.00

Financial

LAST FISCAL CURRENT GROWTH 10 YEAR CAGR
S.NO. COMPANY NAME MARKET CAP CMP BOOK VALUE EPS STOCK P/E ROE ICR REVENUE NET PROFIT NPM REVENUE NET PROFIT REVENUE NET PROFIT
1 SUN PHARMACEUTICAL INDUSTRIES LTD. 159503.05 664.70 98.33 15.69 27.17 15.69 22.95% 32838.00 3765.00 11.47% 12.98% 41.28% 23.41% 10.79%
2 MARKSANS PHARMA LTD. 363666.90 88.60 11.85 2.86 7.08 2.85 21.33% 1134.00 117.00 10.32% 13.40% 53.95% 12.19% 0.00%
3 MOREPEN LABORATORIES LTD. 286978.73 63.75 6.43 0.75 19.67 0.38 34.50% 853.00 34.00 3.99% 10.92% 17.24% 15.16% 0.00%
4 NEULAND LABORATORIES LTD. 256014.20 1997.90 542.16 12.63 37.00 1.23 4.64% 763.00 16.00 2.10% 14.39% 0.00% 10.62% 0.00%
5 GUFIC BIOSCIENCES LTD. 41419.69 53.30 10.85 2.94 24.32 2.88 3.46% 358.00 23.00 6.42% 1.99% 4.55% 19.36% 36.83%
6 DIVI'S LABORATORIES LTD. 112991.73 4258.15 266.77 51.85 37.86 25.98 260.43% 5394.00 1377.00 25.53% 9.06% 1.77% 19.07% 15.01%
7 DR.REDDY'S LABORATORIES LTD. 87720.80 5280.00 852.69 121.92 25.70 24.41 25.28% 17517.00 2026.00 11.57% 13.39% 3.90% 9.56% 19.13%
8 RPG LIFE SCIENCES LTD. 41788.21 252.45 105.02 17.54 16.28 2.23 20.00% 376.00 29.00 7.71% 13.94% 163.64% 8.99% 10.18%
9 Gland Pharma Ltd 51353.02 3141.00 242.00 0.00 0.00 48.31 136.43% 2633.00 773.00 29.36% 28.82% 71.02% 0.00% 0.00%
10 SMS PHARMACEUTICALS LTD. 34236.68 40.25 42.07 3.73 11.38 4.00 6.67% 412.00 32.00 7.77% -11.40% -20.00% 0.00% 0.00%
11 CIPLA LTD. 76607.05 950.50 209.71 19.18 23.33 9.61 16.27% 17132.00 1547.00 9.03% 4.71% 1.24% 12.32% 3.63%
12 TORRENT PHARMACEUTICALS LTD. 48732.26 2878.45 323.66 60.55 33.05 12.06 4.81% 7939.00 1025.00 12.91% 3.47% 135.09% 15.46% 16.07%
13 PIRAMAL ENTERPRISES LTD. 54254.22 2405.40 823.58 1.07 1363.55 0.53 1.18% 13068.00 24.00 0.18% -1.11% -98.37% 13.68% -25.92%
14 LUPIN LTD. 51630.88 1139.45 384.76 -5.95 0.00 -2.96 6.19% 15375.00 -269.00 -1.75% -8.03% -144.32% 12.41% NaN
15 NECTAR LIFESCIENCES LTD. 89651.80 40.00 49.89 1.42 9.79 1.45 1.75% 2363.00 32.00 1.35% -14.97% -33.33% 10.86% -10.02%
16 AUROBINDO PHARMA LTD. 54966.14 938.55 206.07 48.32 10.51 47.98 15.90% 23099.00 2831.00 12.26% 18.07% 19.70% 20.72% 17.53%
17 Alkem Laboratories Ltd 36975.48 3080.00 501.34 94.26 25.32 46.96 22.66% 8344.00 1127.00 13.51% 13.42% 48.09% 0.00% 0.00%
18 ABBOTT INDIA LTD. 34959.61 16395.90 1004.00 279.04 46.86 28.24 84.11% 4093.00 593.00 14.49% 11.25% 31.78% 0.00% 0.00%
19 CADILA HEALTHCARE LTD. 63261.67 617.70 90.85 11.49 23.64 11.54 8.04% 14253.00 1177.00 8.26% 8.26% -36.34% 14.84% 8.83%
20 GLAXOSMITHKLINE PHARMACEUTICALS LTD. 25715.17 1518.30 138.61 5.50 250.36 0.55 18.00% 3224.00 93.00 2.88% 3.07% -79.10% 0.00% 0.00%
Sales

What is Sales Trend ?

Sales trend is a methodology to understand sales results which helps in understanding the trends of the market over a specific period of time. Sales results are an indicative of the sales patterns followed by the customer over a time period.

Profitability
Net Profit
EPS

What is EBITDA Margin & EBIT Margin ?

Corporate accounting is required to adhere to the standards and practices collectively referred to as the generally accepted accounting principles. EBITDA is an excellent way for corporate accountants to start compiling data, but it should not be considered an absolute result. This is due to the fact that many consider EBITDA more of a broad stroke than a definitive form of accounting practice.

EBITDA Margin
EBIT Margin
NPM
Cash Flow

Why is the Cash Flow Analysis important?

A business needs cash to pay its expenses, to pay bank loans, to pay taxes and to purchase new assets. A cash flow report determines whether a business has enough cash to do exactly this.

Operating Activities
Financing Activities
Investing Activities
Financial Health

What Is Financial Health?

Financial health is a term used to describe the state of one's personal monetary affairs. There are many dimensions to financial health, including the amount of savings you have, how much you’re putting away for retirement, and how much of your income you are spending on fixed or non-discretionary expenses.

Debt to Equity
Piotroski Score
  • 0
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9

What Is the Piotroski Score?

The Piotroski score is a discrete score between 0-9 that reflects nine criteria used to determine the strength of a firm's financial position.

Altman Z Score (Mfg Company)
  • Distress (< 1.81)
  • 2.70
    Caution (>1.81 < 2.99)
  • Safe (3 & above)
Altman Z Score (Non-Mfg Company)
  • Distress ( < 1.23)
  • Caution (>1.23 < 2.6)
  • 7.81
    Safe (2.6 & above)
Valuation

What Is Valuation?

Valuation is the analytical process of determining the current (or projected) worth of an asset or a company. There are many techniques used for doing a valuation. An analyst placing a value on a company looks at the business's management, the composition of its capital structure, the prospect of future earnings, and the market value of its assets, among other metrics.

GLENMARK: Future
TRADING SYMBOL OI VOLUME LAST PRICE LOT SIZE EXPIRY DATE
GLENMARK21JUNFUT 1132750.00 1936600.00 629.80 1150.0 2021-06-24
GLENMARK21JULFUT 7258800.00 2570250.00 634.00 1150.0 2021-07-29
GLENMARK21AUGFUT 39100.00 13800.00 635.20 1150.0 2021-08-26
ROLLOVER COST: 0.67% (INR 4.20)
ROLLOVER%:86.56%
What is the significance of Rollover data?

Rollover in an important data point and should be analyzed in the expiry week. Rollover involves carry forwarding of ‘futures’ positions from one series (which is nearing expiry date) to the next one.

Rollover percentage actually indicates whether the traders are willing to carry forward their existing. positions (long or short) to the next series or not. Generally, the rollover figures alone will not indicate which direction traders are betting on. You should also check whether absolute open interest is increasing or decreasing over expiries

What is Options Max Pain Theory?

Options Max Pain Theory suggests,

“On option expiration day, the underlying stock price often moves toward a point that brings maximum loss to option buyers.”

Bulk Deals
Symbol Name Deal Date Client Name Transcation Type Quantity Price
GLENMARK 2013-12-17 MERRILL LYNCH CAPITAL MARKETS ESPANA SA SV P 2149694.00 518.80
GLENMARK 2009-03-24 MERRILL LYNCH CAPITAL MARKETS ESPANA S.A. S.V. S 2713295.00 149.60
GLENMARK 2009-03-24 SR PHOENICIA MAURITIUS LIMITED CLASS A PHOENICIA PORTFOLIO P 2713295.00 149.60
GLENMARK 2006-10-18 HSBC GLOBAL INVESTMENT FU P 7993053.00 380.00
GLENMARK 2006-10-18 CDC INVESTMENT HOLDING LI S 4000000.00 380.00
GLENMARK 2006-10-18 SOUTH ASIA REGIONAL FUND S 4000000.00 380.00
GLENMARK 2005-06-22 CDC INVESTMENT HOLDINGS L S 2015034.00 270.00
GLENMARK 2005-06-22 MORGAN STANLEY INVESTMENT P 1128419.00 270.00
GLENMARK 2004-10-27 CDC FINANCIAL SERVICESFII S 311465.00 308.00
GLENMARK 2004-10-27 SOUTH ASIA REGIONAL FUND S 585267.00 308.00
GLENMARK 2004-10-27 SLOANE ROBINSON INVESTMEN P 1482000.00 308.00
GLENMARK 2004-10-27 CDC FINANCIAL SERVICESFDI S 585268.00 308.00
Block Deals
Symbol Name Deal Date Client Name Transcation Type Quantity Price
GLENMARK 2018-06-04 AL MEHWAR COMMERCIAL INVSTMENTS LLC NOOSA P 970000.00 535.00
GLENMARK 2018-06-04 ABU DHABI INVESTMENT COUNCIL NOOSA S 970000.00 535.00
GLENMARK 2016-08-23 HSBC GLOBAL INVESTMENT FU NDS MAURITIUS LTD S 1100000.00 855.00
GLENMARK 2016-08-23 HSBC GLOBAL INVESTMENT FUNDS INDIAN EQUITY P 1100000.00 855.00
GLENMARK 2012-11-06 THE ROYAL BANK OF SCOTLAND ASIA MERCHANT BANK SINGAPORE LT P 815685.00 438.10
GLENMARK 2012-11-06 ABN AMRO BANK NV S 815685.00 438.10
GLENMARK 2012-10-25 ABN AMRO BANK NV S 400000.00 399.00
GLENMARK 2012-10-25 THE ROYAL BANK OF SCOTLAND ASIA MERCHANT BANK SINGAPORE LT P 400000.00 399.00
GLENMARK 2009-03-26 SR PHOENICIA MAURITIUS LTD P 766258.00 151.50
GLENMARK 2009-03-26 SLOANE ROBINSON INVESTMENT MANAGEMENT S 766258.00 151.50
Dividend history
Bonus Data
Company Name Split Date From Value To Value
No Data Found.
Split Data
Company Name Split Date From Value To Value
No Data Found.